MHR
ANIK icon

Matthew Hamilton Rosenberg’s Anika Therapeutics ANIK Stock Holding History

Matthew Hamilton Rosenberg’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2
Closed -$45 – 856
2023
Q4 		$45 Hold
2
– – ﹤0.01% 904
2023
Q3 		$37 Hold
2
– – ﹤0.01% 923
2023
Q2 		$52 Buy
+2
New +$54 ﹤0.01% 934

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Matthew Hamilton Rosenberg's ANIK Position: Q1 2024 in Review

Matthew Hamilton Rosenberg sold out of Anika Therapeutics (ANIK) in Q1 2024, closing a stake of 2 shares — an estimated $45 sold.

Matthew Hamilton Rosenberg first reported a position in ANIK in Q2 2023 and held it in 3 quarters. The position peaked at $52 in Q2 2023. 120 funds tracked by Wall St. Rank hold ANIK as of Q1 2024.

  • Matthew Hamilton Rosenberg reported no remaining Anika Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Matthew Hamilton Rosenberg sold 2 Anika Therapeutics shares in Q1 2024, an estimated $45.
  • Matthew Hamilton Rosenberg first reported a position in Anika Therapeutics in Q2 2023 and held it in 3 quarters.
  • Matthew Hamilton Rosenberg's Anika Therapeutics position peaked at $52 in Q2 2023.
  • 120 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2024.

Based on Matthew Hamilton Rosenberg's 13F filing for Q1 2024, filed 22 Apr 2024.